Floatz logo

108 assets in Prostate Carcinoma

Therapeutic assets addressing Prostate Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Leuporelin
Prostate Carcinoma
Mayo ClinicP4BBB (74)
Degarelix
Prostate Carcinoma
Baptist Health South FloridaP3BBB (73)
Enzalutamide
Prostate Carcinoma
PfizerP4BBB (73)
Prednisone
Prostate Carcinoma
Mayo ClinicP4BBB (73)
Abiraterone
Prostate Carcinoma
Mayo ClinicP4BBB (72)
Docetaxel
Prostate Carcinoma
Alliance for Clinical Trials in OncologyP3BB (70)
Fludeoxyglucose
Prostate Carcinoma
Jonsson Comprehensive Cancer CenterP2/3BB (69)
Goserelin
Prostate Carcinoma
Mayo ClinicP3BB (69)
AXUMIN
Prostate Carcinoma
NRG OncologyP3BB (66)
Ipilimumab
Prostate Carcinoma
University Hospital, EssenP2BB (66)
Flotufolastat F 18
Prostate Carcinoma
Jonsson Comprehensive Cancer CenterP2BB (65)
Testosterone Undecylate
Prostate Carcinoma
Roswell Park Cancer InstituteP4BB (65)
Apalutamide
Prostate Carcinoma
Alliance for Clinical Trials in OncologyP3BB (64)
Cabozantinib
Prostate Carcinoma
Alfredo BerrutiP2BB (64)
Carboplatin
Prostate Carcinoma
OHSU Knight Cancer InstituteP2BB (64)
Darolutamide
Prostate Carcinoma
UNICANCERP3BB (64)
Olaparib
Prostate Carcinoma
OHSU Knight Cancer InstituteP2BB (64)
Relugolix
Prostate Carcinoma
Baptist Health South FloridaP3BB (64)
Vipivotide Tetraxetan
Prostate Carcinoma
Mayo ClinicP2BB (64)
Bicalutamide
Prostate Carcinoma
Baptist Health South FloridaP3B (63)
Cabazitaxel
Prostate Carcinoma
M.D. Anderson Cancer CenterP2B (62)
Nivolumab
Prostate Carcinoma
National Cancer Institute (NCI)P2B (62)
Pembrolizumab
Prostate Carcinoma
OHSU Knight Cancer InstituteP2B (62)
Florastamin
Prostate Carcinoma
FutureChemP3B (60)
Letrozole
Prostate Carcinoma
Case Comprehensive Cancer CenterP2B (60)
Mevrometostat
Prostate Carcinoma
PfizerP3B (60)
Niclosamide
Prostate Carcinoma
University of California, DavisP2B (60)
Palbociclib
Prostate Carcinoma
OHSU Knight Cancer InstituteP2B (60)
pds01adc
Prostate Carcinoma
National Cancer Institute (NCI)P2B (60)
Pertuzumab
Prostate Carcinoma
OHSU Knight Cancer InstituteP2B (60)
Tamoxifen
Prostate Carcinoma
OHSU Knight Cancer InstituteP2B (60)
Trastuzumab
Prostate Carcinoma
OHSU Knight Cancer InstituteP2B (60)
Trastuzumab Emtansine
Prostate Carcinoma
OHSU Knight Cancer InstituteP2B (60)
Vismodegib
Prostate Carcinoma
OHSU Knight Cancer InstituteP2B (59)
Bendamustine
Prostate Carcinoma
Fred Hutchinson Cancer CenterP2B (58)
Niraparib
Prostate Carcinoma
OHSU Knight Cancer InstituteP2B (58)
Flutamide
Prostate Carcinoma
M.D. Anderson Cancer CenterP2B (57)
Oxybutynin
Prostate Carcinoma
Alliance for Clinical Trials in OncologyP2B (57)
Perflutren Lipid Microsphere Intravenous Suspension
Prostate Carcinoma
Thomas Jefferson UniversityP3B (57)
Tadalafil
Prostate Carcinoma
Regina Elena Cancer InstituteP3B (57)
Pyruvate
Prostate Carcinoma
Ivan de Kouchkovsky, MDP2B (56)
Methylphenidate
Prostate Carcinoma
M.D. Anderson Cancer CenterP2/3CCC (55)
Abemaciclib
Prostate Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Binimetinib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Capivasertib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cetrelimab
Prostate Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Crizotinib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Dabrafenib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Dasatinib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Defactinib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Showing 1 to 50 of 108 assets
PreviousPage 1 of 3Next